Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Consensus Target Price of $11.33 According to Brokerages

Key Points

• Analyst sentiment is broadly positive: Nine brokerages give Aclaris Therapeutics an average “Buy” rating, with a consensus 12-month price target of $11.33 versus the reported share price of $5.28.
• Recent coverage included an “Outperform” rating with a $13 target from Lifesci Capital and a “Buy” rating with a $10 target from Canaccord Genuity, while Weiss Ratings maintained a “Sell” rating.
• Aclaris exceeded quarterly expectations, reporting an adjusted loss of $0.15 per share versus $0.16 expected and revenue of $1.63 million versus $1.38 million estimated; however, the company remains deeply unprofitable, with a negative net margin of 921.50%.

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned an average recommendation of "Buy" from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and three have given a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $11.33.

A number of analysts recently weighed in on ACRS shares. Lifesci Capital started coverage on Aclaris Therapeutics in a report on Tuesday, June 2nd. They issued an "outperform" rating and a $13.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aclaris Therapeutics in a report on Monday, September 21st. Finally, Canaccord Genuity Group assumed coverage on Aclaris Therapeutics in a research report on Tuesday, September 1st. They issued a "buy" rating and a $10.00 price target on the stock.

Aclaris Therapeutics Price Performance

Shares of NASDAQ ACRS opened at $5.28 on Wednesday. The company has a 50 day simple moving average of $5.77 and a 200 day simple moving average of $4.95. The firm has a market cap of $738.25 million, a PE ratio of -9.10 and a beta of 0.79. Aclaris Therapeutics has a 1 year low of $1.74 and a 1 year high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The firm had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. As a group, research analysts anticipate that Aclaris Therapeutics will post -0.62 earnings per share for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Aclaris Therapeutics in the 2nd quarter worth approximately $53,096,000. Rock Springs Capital Management LP raised its stake in Aclaris Therapeutics by 0.4% during the first quarter. Rock Springs Capital Management LP now owns 4,472,650 shares of the biotechnology company's stock worth $16,772,000 after buying an additional 18,909 shares during the last quarter. Braidwell LP lifted its holdings in Aclaris Therapeutics by 26.1% in the second quarter. Braidwell LP now owns 2,142,348 shares of the biotechnology company's stock valued at $11,333,000 after buying an additional 443,232 shares during the period. Kalehua Capital Management LLC bought a new stake in Aclaris Therapeutics during the first quarter valued at $6,871,000. Finally, Palo Alto Investors LP acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth about $8,535,045. Institutional investors and hedge funds own 98.34% of the company's stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated and inflammatory diseases. The company's research programs are centered on potentially addressing conditions in which existing treatments have limited effectiveness or tolerability.

Aclaris has developed a pipeline that has included zunsemetinib, an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being studied for inflammatory diseases, and other small-molecule therapies targeting immune and inflammatory pathways.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.